<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3461">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331808</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200375-1</org_study_id>
    <nct_id>NCT04331808</nct_id>
  </id_info>
  <brief_title>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</brief_title>
  <acronym>CORIMUNO-TOC</acronym>
  <official_title>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to determine the therapeutic effect and tolerance of
      Tocizilumab in patients with moderate, severe pneumonia or critical pneumonia associated with
      Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor
      monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study
      has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur
      prior to offering Tocilizumab administration to patients enrolled in the COVIMUNO-19 cohort.
      Tocilizumab will be administered to consenting adult patients hospitalized with CORVID-19
      either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or
      critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive
      Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be
      compared with outcomes of standard of care treated patients as well as outcomes of patients
      treated with other immune modulators.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without needs of ventilator utilization at day 14. Group 1</measure>
    <time_frame>14 days</time_frame>
    <description>Group 1. Survival without needs of ventilator utilization (including non invasive ventilation and high flow) at day 14. Thus, events considered are needing ventilator utilization (including Non Invasive Ventilation, NIV or high flow), or death. New DNR order (if given after the inclusion of the patient) will be considered as an event at the date of the DNR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO progression scale &lt;=5 at day 4. Group 1.</measure>
    <time_frame>4 days</time_frame>
    <description>Group 1. Proportion of patients alive without non-invasive ventilation of high low at day 4 (WHO progression scale ≤ 5). A patient with new DNR order at day 4 will be considered as with a score &gt; 5.
WHO progression scale:
Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14. Group 2.</measure>
    <time_frame>14 days</time_frame>
    <description>Group 2. Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14 if patients have been intubated before day 14 ; or removal of NIV or high flow (for &gt; 48h) if they were included under oxygen by NIV or High flow (score 6) and remained without intubation. Death or new DNR order (if given after the inclusion of the patient) will be considered as a competing event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO progression scale at day 4. Group 2.</measure>
    <time_frame>4 days</time_frame>
    <description>Group 2 Early end point : proportion of patients with a decrease of WHO score of at least 1 point at day 4.
WHO progression scale:
Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO progression scale</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>WHO progression scale:
Uninfected; non viral RNA detected: 0 Asymptomatic; viral RNA detected: 1 Symptomatic; Independent: 2 Symptomatic; Assistance needed: 3 Hospitalized; No oxygen therapy: 4 Hospitalized; oxygen by mask or nasal prongs: 5 Hospitalized; oxygen by NIV or High flow: 6 Intubation and Mechanical ventilation, pO2/FIO2&gt;=150 OR SpO2/FIO2&gt;=200: 7 Mechanical ventilation, (pO2/FIO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min): 8 Mechanical ventilation, pO2/FIO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO: 9 Dead: 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14, 28 and 90 days</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day ventilator free-days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory acidosis at day 4</measure>
    <time_frame>4 days</time_frame>
    <description>arterial blood pH of &lt;7.25 with a partial pressure of arterial carbon dioxide [Paco2] of ≥60 mm Hg for &gt;6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>evolution of PaO2/FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to oxygen supply independency</measure>
    <time_frame>14 days</time_frame>
    <description>time to oxygen supply independency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to negative viral excretion</measure>
    <time_frame>90 days</time_frame>
    <description>time to negative viral excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to ICU discharge</measure>
    <time_frame>90 days</time_frame>
    <description>time to ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to hospital discharge</measure>
    <time_frame>90 days</time_frame>
    <description>time to hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>TOCILIZUMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.</description>
    <arm_group_label>TOCILIZUMAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients included in the CORIMUNO-19 cohort

          2. Patients belonging to one of the 2 following groups:

               -  Group 1: Cases meeting all of the following criteria

                    -  Requiring more than 3L/min of oxygen

                    -  OMS/WHO progression scale = 5

                    -  No NIV or High flow

               -  Group 2: Cases meeting all of the following criteria

                    -  Respiratory failure AND (requiring mechanical ventilation OR NIV OR High
                       flow)

                    -  WHO progression scale &gt;=6

                    -  No do-not-resuscitate order (DNR order)

        Exclusion Criteria:

          -  Patients with exclusion criteria to the CORIMUNO-19 cohort.

          -  Known hypersensitivity to Tocilizumab or to any of their excipients.

          -  Pregnancy

          -  Current documented bacterial infection

          -  Patient with any of following laboratory results out of the ranges detailed below at
             screening should be discussed depending of the medication:

          -  Absolute neutrophil count (ANC) ≤ 1.0 x 109/L

          -  Haemoglobin level: no limitation

          -  Platelets (PLT) &lt; 50 G /L

          -  SGOT or SGPT &gt; 5N
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>APHP- Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Beaujon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

